When deciding whether to continue screening mammography with older breast cancer survivors, consider life expectancy, experts said.
Life expectancy should be the driving force behind whether older breast cancer survivors continue with screening mammography.
At least that is the push behind the first screening mammography guidelines published Thursday, Jan. 28, for this patient group. A national panel of experts shared their recommendations in JAMA Oncology.
The group, led by Rachel A. Freedman, M.D., MPH, medical director of the Dana-Farber Cancer Institute Cancer Care Collaborative, noted that these guidelines are not prescriptive, but they are an excellent starting point for discussing mammography plans and options with older patients.
Related Content: Better Understanding of Screening Mammography Cuts Imaging Rates Among Older Women
“The purpose of the guidelines is to offer clinicians support for having these conversations with patients and to make a shared individualized decision for each woman,” she said, noting that printed materials designed to help patients gauge their recurrence risk and weigh the up- and downsides of mammography will be available.
The current standard-of-care with mammography for all breast cancer survivors is annual screening. But, little direction exists, she added, for how providers should tailor services for older women and whether life expectancy, recurrence risk, patient preferences, or tradeoffs associated with the exam should play a role in any decisions.
“The result is that the use of mammography for older survivors has been highly inconsistent,” Freedman said. “With the number of older women who will be diagnosed with breast cancer expected to increase in the coming years, it’s important that we find ways to individualizer decisions for each patient’s circumstances and preferences.”
Related Content: Mammography in Older Women and Life Expectancy
Those are the questions a group of representatives from breast cancer primary care, geriatrics, radiology, survivorship, and nursing groups sought to answer. They were joined by an 18-member patient panel to review existing literature around the risks of breast cancer in older women. They also considered the pros and cons of continuing mammography in these older patients.
From their discussion, the group drafted these guidelines, which were reviewed by the International Society for Geriatric Oncology:
Based on their literature review, the team determined mammography offers older women little-to-moderate benefit, and it can produce false positives that can lead to anxiety, unnecessary testing, and over-treatment. Fortunately, they said, older breast cancer survivors have a low risk of breast cancer in either breast, especially those women who have previously received treatment with hormone-blocking therapy for hormone receptor-positive tumors.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.